{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:54Z","timestamp":1794047454027,"version":"4.8.0"},"reference-count":38,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"4","license":[{"start":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T00:00:00Z","timestamp":1695859200000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Multiple myeloma (MM) remains incurable due to drug resistance. Ribosomal protein S3 (RPS3) has been identified as a non-Rel subunit of NF-\u03baB. However, the detailed biological roles of RPS3 remain unclear. Here, we report for the first time that RPS3 is necessary for MM survival and drug resistance. RPS3 was highly expressed in MM, and knockout of RPS3 in MM inhibited cell growth and induced cell apoptosis both in vitro and in vivo. Overexpression of RPS3 mediated the proteasome inhibitor resistance of MM and shortened the survival of MM tumor-bearing animals. Moreover, our present study found an interaction between RPS3 and the thyroid hormone receptor interactor 13 (TRIP13), an oncogene related to MM tumorigenesis and drug resistance. We demonstrated that the phosphorylation of RPS3 was mediated by TRIP13 via PKC\u03b4, which played an important role in activating the canonical NF-\u03baB signaling and inducing cell survival and drug resistance in MM. Notably, the inhibition of NF-\u03baB signaling by the small-molecule inhibitor targeting TRIP13, DCZ0415, was capable of triggering synergistic cytotoxicity when combined with bortezomib in drug-resistant MM. This study identifies RPS3 as a novel biomarker and therapeutic target in MM.<\/jats:p>","DOI":"10.3324\/haematol.2023.282789","type":"journal-article","created":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T15:28:31Z","timestamp":1695914911000},"page":"1206-1219","source":"Crossref","is-referenced-by-count":12,"title":["Ribosomal protein S3 mediates drug resistance of proteasome inhibitor: potential therapeutic application in multiple myeloma"],"prefix":"10.3324","volume":"109","author":[{"given":"Gege","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuejie","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyan","family":"Jia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingcong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dandan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuaikang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Deng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guanli","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yumeng","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huaping","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongliang","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosong","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huabin","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiliang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jumei","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,9,28]]},"reference":[{"key":"59769","doi-asserted-by":"crossref","unstructured":"van de Donk N, Pawlyn C, Yong KL. Multiple myeloma. Lancet. 2021; 397(10272):410-427.","DOI":"10.1016\/S0140-6736(21)00135-5"},{"key":"59770","doi-asserted-by":"crossref","unstructured":"Cowan AJ, Green DJ, Kwok M. Diagnosis and management of multiple myeloma: a review. JAMA. 2022; 327(5):464-477.","DOI":"10.1001\/jama.2022.0003"},{"key":"59771","doi-asserted-by":"crossref","unstructured":"Nishida H. Rapid progress in immunotherapies for multiple myeloma: an updated comprehensive review. Cancers (Basel). 2021; 13(11):4.","DOI":"10.3390\/cancers13112712"},{"key":"59772","doi-asserted-by":"crossref","unstructured":"Podar K, Leleu X. Relapsed\/refractory multiple myeloma in 2020\/2021 and beyond. Cancers (Basel). 2021; 13(20):5.","DOI":"10.3390\/cancers13205154"},{"key":"59773","doi-asserted-by":"crossref","unstructured":"Alagpulinsa DA, Szalat RE, Poznansky MC, Shmookler Reis RJ. Genomic instability in multiple myeloma. Trends Cancer. 2020; 6(10):858-873.","DOI":"10.1016\/j.trecan.2020.05.006"},{"key":"59774","doi-asserted-by":"crossref","unstructured":"Neri P, Bahlis NJ. Genomic instability in multiple myeloma: mechanisms and therapeutic implications. Expert Opin Biol Ther. 2013; 13:S69-82.","DOI":"10.1517\/14712598.2013.814637"},{"key":"59775","doi-asserted-by":"crossref","unstructured":"Mitterer V, Murat G, Rety S. Sequential domain assembly of ribosomal protein S3 drives 40S subunit maturation. Nat Commun. 2016; 7:10336.","DOI":"10.1038\/ncomms10336"},{"key":"59776","doi-asserted-by":"crossref","unstructured":"Lee SB, Kwon IS, Park J. Ribosomal protein S3, a new substrate of Akt, serves as a signal mediator between neuronal apoptosis and DNA repair. J Biol Chem. 2010; 285(38):29457-29468.","DOI":"10.1074\/jbc.M110.131367"},{"key":"59777","doi-asserted-by":"crossref","unstructured":"Gao X, Hardwidge PR. Ribosomal protein s3: a multifunctional target of attaching\/effacing bacterial pathogens. Front Microbiol. 2011; 2:137.","DOI":"10.3389\/fmicb.2011.00137"},{"key":"59778","doi-asserted-by":"crossref","unstructured":"Graifer D, Malygin A, Zharkov DO, Karpova G. Eukaryotic ribosomal protein S3: a constituent of translational machinery and an extraribosomal player in various cellular processes. Biochimie. 2014; 99:8-18.","DOI":"10.1016\/j.biochi.2013.11.001"},{"key":"59779","doi-asserted-by":"crossref","unstructured":"Wan F, Anderson DE, Barnitz RA. Ribosomal protein S3: a KH domain subunit in NF-kappaB complexes that mediates selective gene regulation. Cell. 2007; 131(5):927-939.","DOI":"10.1016\/j.cell.2007.10.009"},{"key":"59780","doi-asserted-by":"crossref","unstructured":"Wan F, Lenardo MJ. The nuclear signaling of NF-kappaB: current knowledge, new insights, and future perspectives. Cell Res. 2010; 20(1):24-33.","DOI":"10.1038\/cr.2009.137"},{"key":"59781","doi-asserted-by":"crossref","unstructured":"Wan F, Weaver A, Gao X, Bern M, Hardwidge PR, Lenardo MJ. IKKbeta phosphorylation regulates RPS3 nuclear translocation and NF-kappaB function during infection with Escherichia coli strain O157:H7. Nat Immunol. 2011; 12(4):335-343.","DOI":"10.1038\/ni.2007"},{"key":"59782","doi-asserted-by":"crossref","unstructured":"Yang HJ, Youn H, Seong KM, Jin YW, Kim J, Youn B. Phosphorylation of ribosomal protein S3 and antiapoptotic TRAF2 protein mediates radioresistance in non-small cell lung cancer cells. J Biol Chem. 2013; 288(5):2965-2975.","DOI":"10.1074\/jbc.M112.385989"},{"key":"59783","doi-asserted-by":"crossref","unstructured":"Tao Y, Yang G, Yang H. TRIP13 impairs mitotic checkpoint surveillance and is associated with poor prognosis in multiple myeloma. Oncotarget. 2017; 8(16):26718-26731.","DOI":"10.18632\/oncotarget.14957"},{"key":"59784","doi-asserted-by":"crossref","unstructured":"Li C, Xia J, Franqui-Machin R. TRIP13 modulates protein deubiquitination and accelerates tumor development and progression of B cell malignancies. J Clin Invest. 2021; 131(14):e146893.","DOI":"10.1172\/JCI146893"},{"key":"59785","doi-asserted-by":"crossref","unstructured":"Wang Y, Huang J, Li B. A small-molecule inhibitor targeting TRIP13 suppresses multiple myeloma progression. Cancer Res. 2020; 80(3):536-548.","DOI":"10.1158\/0008-5472.CAN-18-3987"},{"key":"59786","doi-asserted-by":"crossref","unstructured":"Lan J, Huang J, Tao X. Evaluation of the TRIP13 level in breast cancer and insights into potential molecular pathways. J Cell Mol Med. 2022; 26(9):2673-2685.","DOI":"10.1111\/jcmm.17278"},{"key":"59787","doi-asserted-by":"crossref","unstructured":"Sheng N, Yan L, Wu K. TRIP13 promotes tumor growth and is associated with poor prognosis in colorectal cancer. Cell Death Dis. 2018; 9(3):402.","DOI":"10.1038\/s41419-018-0434-z"},{"key":"59788","doi-asserted-by":"crossref","unstructured":"Li W, Zhang G, Li X. Thyroid hormone receptor interactor 13 (TRIP13) overexpression associated with tumor progression and poor prognosis in lung adenocarcinoma. Biochem Biophys Res Commun. 2018; 499(3):416-424.","DOI":"10.1016\/j.bbrc.2018.03.129"},{"key":"59789","doi-asserted-by":"crossref","unstructured":"Banerjee R, Russo N, Liu M. TRIP13 promotes error-prone nonhomologous end joining and induces chemoresistance in head and neck cancer. Nat Commun. 2014; 5:4527.","DOI":"10.1038\/ncomms5527"},{"key":"59790","doi-asserted-by":"crossref","unstructured":"Alfieri C, Chang L, Barford D. Mechanism for remodelling of the cell cycle checkpoint protein MAD2 by the ATPase TRIP13. Nature. 2018; 559(7713):274-278.","DOI":"10.1038\/s41586-018-0281-1"},{"key":"59791","doi-asserted-by":"crossref","unstructured":"Ye Q, Rosenberg SC, Moeller A, Speir JA, Su TY, Corbett KD. TRIP13 is a protein-remodeling AAA+ ATPase that catalyzes MAD2 conformation switching. Elife. 2015; 4:e07367.","DOI":"10.7554\/eLife.07367"},{"key":"59792","doi-asserted-by":"crossref","unstructured":"Sarangi P, Clairmont CS, Galli LD, Moreau LA, D\u2019Andrea AD. p31(comet) promotes homologous recombination by inactivating REV7 through the TRIP13 ATPase. Proc Natl Acad Sci U S A. 2020; 117(43):26795-26803.","DOI":"10.1073\/pnas.2008830117"},{"key":"59793","doi-asserted-by":"crossref","unstructured":"Hu L, Li B, Chen G. A novel M phase blocker, DCZ3301 enhances the sensitivity of bortezomib in resistant multiple myeloma through DNA damage and mitotic catastrophe. J Exp Clin Cancer Res. 2020; 39(1):105.","DOI":"10.1186\/s13046-020-01597-9"},{"key":"59794","doi-asserted-by":"crossref","unstructured":"Xie Y, Wang Y, Xu Z. Preclinical validation and phase I trial of 4-hydroxysalicylanilide, targeting ribonucleotide reductase mediated dNTP synthesis in multiple myeloma. J Biomed Sci. 2022; 29(1):32.","DOI":"10.1186\/s12929-022-00813-2"},{"key":"59795","doi-asserted-by":"crossref","unstructured":"Chen G, Hu K, Sun H. A novel phosphoramide compound, DCZ0847, displays in vitro and in vivo anti-myeloma activity, alone or in combination with bortezomib. Cancer Lett. 2020; 478:45-55.","DOI":"10.1016\/j.canlet.2020.03.006"},{"key":"59796","doi-asserted-by":"crossref","unstructured":"Kim TS, Kim HD, Kim J. PKCdelta-dependent functional switch of rpS3 between translation and DNA repair. Biochim Biophys Acta. 2009; 1793(2):395-405.","DOI":"10.1016\/j.bbamcr.2008.10.017"},{"key":"59797","doi-asserted-by":"crossref","unstructured":"Kim TS, Kim HD, Shin HS, Kim J. Phosphorylation status of nuclear ribosomal protein S3 is reciprocally regulated by protein kinase Cdelta and protein phosphatase 2A. J Biol Chem. 2009; 284(32):21201-21208.","DOI":"10.1074\/jbc.M109.018168"},{"key":"59798","doi-asserted-by":"crossref","unstructured":"Robak P, Drozdz I, Szemraj J, Robak T. Drug resistance in multiple myeloma. Cancer Treat Rev. 2018; 70:199-208.","DOI":"10.1016\/j.ctrv.2018.09.001"},{"key":"59799","doi-asserted-by":"crossref","unstructured":"Nagao-Kitamoto H, Setoguchi T, Kitamoto S. Ribosomal protein S3 regulates GLI2-mediated osteosarcoma invasion. Cancer Lett. 2015; 356(2 Pt B):855-861.","DOI":"10.1016\/j.canlet.2014.10.042"},{"key":"59800","doi-asserted-by":"crossref","unstructured":"Tian Y, Qin L, Qiu H. RPS3 regulates melanoma cell growth and apoptosis by targeting Cyto C\/Ca2+\/MICU1 dependent mitochondrial signaling. Oncotarget. 2015; 6(30):29614-29625.","DOI":"10.18632\/oncotarget.4868"},{"key":"59801","doi-asserted-by":"crossref","unstructured":"Kim W, Youn H, Lee S. RNF138-mediated ubiquitination of rpS3 is required for resistance of glioblastoma cells to radiation-induced apoptosis. Exp Mol Med. 2018; 50(1):e434.","DOI":"10.1038\/emm.2017.247"},{"key":"59802","doi-asserted-by":"crossref","unstructured":"Baud V, Karin M. Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls. Nat Rev Drug Discov. 2009; 8(1):33-40.","DOI":"10.1038\/nrd2781"},{"key":"59803","doi-asserted-by":"crossref","unstructured":"Vrabel D, Pour L, Sevcikova S. The impact of NF-kappaB signaling on pathogenesis and current treatment strategies in multiple myeloma. Blood Rev. 2019; 34:56-66.","DOI":"10.1016\/j.blre.2018.11.003"},{"key":"59804","doi-asserted-by":"crossref","unstructured":"Vo JN, Wu YM, Mishler J. The genetic heterogeneity and drug resistance mechanisms of relapsed refractory multiple myeloma. Nat Commun. 2022; 13(1):3750.","DOI":"10.1038\/s41467-022-31430-0"},{"key":"59805","doi-asserted-by":"crossref","unstructured":"Fabre C, Mimura N, Bobb K. Dual inhibition of canonical and noncanonical NF-kappaB pathways demonstrates significant antitumor activities in multiple myeloma. Clin Cancer Res. 2012; 18(17):4669-4681.","DOI":"10.1158\/1078-0432.CCR-12-0779"},{"key":"59806","doi-asserted-by":"crossref","unstructured":"Moreau P, Richardson PG, Cavo M. Proteasome inhibitors in multiple myeloma: 10 years later. Blood. 2012; 120(5):947-959.","DOI":"10.1182\/blood-2012-04-403733"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282789\/76145","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.282789\/76790","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11279\/76145","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:57Z","timestamp":1794045897000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.282789"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,28]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,3,31]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.282789","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,9,28]]}}}